Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose.

Radionuclide therapy is a rapidly expanding oncological treatment method. Overwhelmingly, the application of radionuclide therapy in clinical practice relies on fixed or empirical dosing strategies. In principle, the application of dosimetry promises to improve patient outcomes by tailoring administered radionuclide therapy activities to each patient's unique tumour burden and tumour uptake. However, robust prospective data are scarce due to few prospective randomised clinical trials investigating the use of dosimetry in radionuclide therapy. In this Review, we describe the role of dosimetry as it has been applied historically and in modern clinical practice and its potential future applications. We further emphasise areas of future growth and a potential pathway to optimised personalised activity modulation of radionuclide therapy.
Competing Interests: Declaration of interests TAH declares research grants from Clovis Oncology and AAA/Novartis; consulting fees from Curium, Ipsen, and Blue Earth Diagnostics; a leadership role in the North American Neuroendocrine Tumor Society; and stock or stock options in RayzeBio, a radiopharmaceuticals company. EKF declares consulting fees for dosimetry from Invicro and Ymabs. RRF declares a research grant from the US Department of Defense Prostate Cancer Research Program on radionuclide therapy development. All other authors declare no competing interests.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)